文献速递糖尿病

从生存到自由:重新定义1型糖尿病的治疗成功

From survival to freedom: redefining success in type 1 diabetes.
PubMed 文献 · Lancet Diabetes Endocrinol · 2026-02-25

本文为Lancet Diabetes Endocrinol个人观点文章,指出强化胰岛素治疗、持续葡萄糖监测与混合闭环系统已使1型糖尿病从早期致死性疾病转为慢性病,但残余超额死亡与心血管风险仍持续存在。作者主张将治疗成功标准从单纯血糖指标转向恢复内源性调控与生理韧性,并以代谢稳定、严重低血糖防护及认知与治疗负担下降来衡量。

要点

  • 1型糖尿病残余超额死亡与心血管风险仍存,与早期血糖异常的代谢和表观遗传记忆相关。
  • HbA1c进一步降低在人群层面未带来成比例结局改善,治疗目标应转向生理韧性。
  • β细胞替代治疗应以持久性、安全性、C肽保留、严格范围时间和患者报告结局评价。

核心结论

  • 1型糖尿病治疗成功应从生存延长与血糖指标,重新定义为恢复内源性调控与生理韧性。
  • 成功应以持续代谢稳定、严重低血糖防护及认知和治疗负担显著降低来操作化衡量。

研究设计与样本

  • 本文为个人观点(Personal View)文章,非系统检索或原始研究,未报告样本量与检索范围。

主要发现

  • 强化胰岛素治疗、持续葡萄糖监测和混合闭环系统使近正常血糖成为可及目标。
  • 残余超额死亡与心血管风险持续存在,被认为反映早期血糖异常的长期生物学遗留。
  • 随生存期延长,疾病负担日益转向认知下降、抑郁、感染和癌症,日常管理负担仍高。
  • 证据提示HbA1c进一步降低在人群层面未转化为成比例的结局改善。

关键数值与推荐

  • β细胞替代(胰腺或胰岛移植及新兴干细胞来源植入物)应少以平均HbA1c评判。
  • 应以持久性、安全性、C肽保留、严格范围时间和经验证的患者报告结局评判β细胞替代。
  • 监管与经济框架应接纳多维获益。

临床怎么用

  • 内分泌科评估1型糖尿病治疗时,除HbA1c外应关注血糖变异性、低血糖防护与患者报告结局。
  • 对β细胞替代疗法应综合评估持久性、安全性、C肽保留及严格范围时间。
  • 治疗决策应兼顾认知与治疗负担,追求更接近生理的代谢状态。

局限性

  • 本文为个人观点文章,未提供系统检索策略、样本量或定量合并结果。
  • 文中关于代谢与表观遗传记忆、认知下降及癌症等表述为观点性归纳,未给出具体数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Type 1 diabetes has shifted from a condition once associated with early mortality to a chronic disease owing to the development of intensive insulin therapy, continuous glucose monitoring, and hybrid closed-loop systems. Despite near-normoglycaemia becoming an attainable target, residual excess mortality and cardiovascular risk persist. These outcomes are thought to reflect the long-term biological legacy of earlier dysglycaemia, including metabolic and epigenetic memory associated with inflammatory and vascular vulnerability. As survival for people with type 1 diabetes lengthens, morbidity increasingly shifts towards cognitive decline, depression, infections, and cancer, whereas the lived burden of daily disease management remains high. As evidence suggests that further reductions in HbA1c do not translate into proportional improvements in outcomes at the population level, the next therapeutic frontier becomes physiological resilience: interventions that restore endogenous regulation, reduce glycaemic variability, and dampen inflammatory stress, thereby approximating a more physiological metabolic state. β-cell replacement-via pancreas or islet transplantation and emerging stem cell-derived implants-should be judged less by mean HbA1c and more by durability, safety, C-peptide preservation, time in (tight) range, and validated patient-reported outcomes. Regulatory and economic frameworks must consequently embrace multidimensional benefits. Within this evolving framework, success is measured not only by longer survival, but also by improved physiological control achieved with minimal toxicity and reduced cognitive burden. This Personal View argues for reframing therapeutic success in type 1 diabetes by shifting the focus from glycaemic metrics alone to the restoration of endogenous regulation and physiological resilience-outcomes operationalised as sustained metabolic stability, protection from severe hypoglycaemia, and a substantial reduction in cognitive and therapeutic burden.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Piemonti L. From survival to freedom: redefining success in type 1 diabetes. Lancet Diabetes Endocrinol. 2026. PMID: 41763233. doi:10.1016/S2213-8587(26)00003-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。